全球增生性糖尿病視網膜病變市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計增殖性糖尿病視網膜病變市場將從 2025 年的 38.9 億美元成長到 2034 年的 82.1 億美元，2026 年至 2034 年的複合年成長率為 8.66%。

隨著全球糖尿病及其併發症的增加，增殖性糖尿病視網膜病變（PDR）市場正穩定成長。增殖性糖尿病視網膜病變（PDR）是嚴重的眼科疾病，如不及時治療可導致視力喪失。人們對糖尿病眼疾篩檢的認知不斷提高，以及視網膜影像技術的進步，都促進了早期發現和治療。開發中國家醫療保健服務的普及也推動了市場成長。

關鍵促進因素包括抗VEGF療法、雷射光凝術和玻璃體切除術的日益普及。藥物創新和臨床研究正在提高治療效果和患者預後。此外，篩檢計畫的改進和遠距眼科服務的普及使得及時診斷成為可能，尤其是在偏遠地區。糖尿病患者數量的不斷成長，尤其是在亞太地區和北美地區，顯著支撐了對增殖性糖尿病視網膜病變（PDR）治療方案的持續需求。

生物製藥、緩釋藥物傳遞系統和基因療法的進步為未來帶來了廣闊的前景。人工智慧驅動的視網膜篩檢工具有望提高診斷效率。針對糖尿病管理的公共衛生措施的不斷加強將進一步擴大治療範圍。隨著早期療育的普及，增殖性糖尿病視網膜病變市場預計將在未來幾年保持穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球增殖性糖尿病視網膜病變市場：依藥物類別分類

• 市場分析、洞察與預測
• 抗 VEGF 藥物
• 皮質類固醇

第5章：增殖性糖尿病視網膜病變全球市場：依給藥途徑分類

• 市場分析、洞察與預測
• 注射藥物
• 口服
• 其他

第6章：全球增殖性糖尿病視網膜病變市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球增殖性糖尿病視網膜病變市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Genentech Inc
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • Pfizer Inc
  • Merck KGaA
  • Cipla Inc
  • AbbVie Inc
  • Bausch Health Companies Inc
  • Santen Pharmaceutical Co. Ltd
  • Alimera Sciences
  • Intas Pharmaceuticals Ltd

The Proliferative Diabetic Retinopathy Market size is expected to reach USD 8.21 Billion in 2034 from USD 3.89 Billion (2025) growing at a CAGR of 8.66% during 2026-2034.

The Global Proliferative Diabetic Retinopathy Market is growing steadily due to the increasing global burden of diabetes and related complications. Proliferative diabetic retinopathy (PDR) is a severe eye condition that can lead to vision loss if untreated. Rising awareness regarding diabetic eye screening and advancements in retinal imaging technologies are supporting early detection and treatment. Expanding healthcare access in developing economies is also contributing to market growth.

Major drivers include the increasing adoption of anti-VEGF therapies, laser photocoagulation procedures, and vitrectomy surgeries. Pharmaceutical innovation and clinical research are enhancing treatment effectiveness and patient outcomes. Additionally, improved screening programs and tele-ophthalmology services are enabling timely diagnosis, particularly in remote areas. The growing diabetic population, especially in Asia-Pacific and North America, significantly supports sustained demand for PDR treatment solutions.

Future prospects appear promising with advancements in biologics, sustained-release drug delivery systems, and gene-based therapies. Artificial intelligence-assisted retinal screening tools are expected to improve diagnostic efficiency. Increasing public health initiatives targeting diabetes management will further expand treatment coverage. As early intervention becomes more accessible, the proliferative diabetic retinopathy market is projected to maintain steady growth over the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Anti-VEGF Agents
• Corticosteroids

By Mode of Administration

• Injectable
• Oral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Genentech Inc, Novartis AG, Regeneron Pharmaceuticals Inc, Pfizer Inc, Merck KGaA, Cipla Inc, AbbVie Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences, Intas Pharmaceuticals Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Anti-VEGF Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY MODE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mode Of Administration
• 5.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Mode Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Mode Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Mode Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Mode Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Mode Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Genentech Inc
  • 9.2.2 Novartis AG
  • 9.2.3 Regeneron Pharmaceuticals Inc
  • 9.2.4 Pfizer Inc
  • 9.2.5 Merck KGaA
  • 9.2.6 Cipla Inc
  • 9.2.7 AbbVie Inc
  • 9.2.8 Bausch Health Companies Inc
  • 9.2.9 Santen Pharmaceutical Co. Ltd
  • 9.2.10 Alimera Sciences
  • 9.2.11 Intas Pharmaceuticals Ltd